Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of alternating mFOLFOX and mFOLFIRI as second-line treatment for advanced biliary tract cancer
KCT0010326Phase 2Recruiting
- Sponsor
- Boryung
- Start
- Aug 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, irinotecan, folinic acid, fluorouracil in biliary cancer, cholangiocarcinoma (CCA), gallbladder cancer, Ampullary cancer (AC), sponsored by Boryung. Started Aug 2025; status: recruiting.
02
Drugs
oxaliplatinirinotecanfolinic acidfluorouracil
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on KCT0010326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010326.